Navigation Links
HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device
Date:11/9/2007

Provides 10 puncture skin tests at once with minimal patient discomfort

SPOKANE, Wash., Nov. 9 /PRNewswire/ -- HollisterStier's Allergy Business Unit announced today the launch of the ComforTen(TM) Multiple Skin Test System, its newest allergy testing device. The device features ten surgical steel 1.2mm lancet tips, which create minimal skin trauma for comfortable allergy testing. ComforTen is the only 10-test, self-loading, surgical steel testing device on the market. ComforTen is competitively priced relative to other multiple skin test devices available today. In addition to creating a more comfortable experience for the patient; little or no trauma at the negative control site makes it easy to read skin test reactions.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060228/SFTU141LOGO)

Derek Constable, Ph.D., Director of New Product Discovery at HollisterStier, said, "ComforTen was developed with the Allergists, nurses, and the patients in mind. We have made every effort to create a comfortable allergy testing experience for all parties. We're excited to introduce this new addition to the full suite of HollisterStier products."

In addition to the device itself, the ComforTen System includes trays with three optional-use spacers (patent pending) that increase the number of tests that can be completed between fillings. "We heard allergy offices tell us they wanted a skin testing device that maximized efficiency and the ComforTen System does that," Constable said. The trays are also supplied with self-adhesive labels allowing for customized tray labeling.

When used as directed, the ComforTen device with depth control guards will produce ten reproducible skin tests resulting in well-defined reactions. The device is equipped with directional indicators to help ensure the proper orientation and application.

About HollisterStier's Allergy Business Unit

HollisterStier Laboratories LLC (http://www.hollisterstier.com) is a leading Contract Manufacturer of Sterile Injectable and Lyophilization products and one of the world's top producers of Allergenic Extracts.

It has specific manufacturing capabilities in Lyophilization, Vial Filling, Aseptic Filling and Allergenic Extracts. The company has leading pharmaceutical, generic, and biotechnology companies as its customers. The Company's product portfolio in specialized allergenic extracts includes Mites, Venom and the Acetone Precipitated(TM) line of products; including APTM Dog. HollisterStier's line of skin testing devices include QUINTIP(R), QUINTEST(R), and now ComforTen(TM). HollisterStier Laboratories LLC is owned by Jubilant Organosys Ltd. (http://www.jubl.com).

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceuticals value chain: from drug discovery, functional chemistry and clinical research services to custom research and manufacturing services for advance intermediates and fine chemicals, Active Pharmaceutical Ingredients and Dosage Forms.

Jubilant Organosys has geographically diversified manufacturing facilities in seven locations. Of these, five are in India and two in USA are in Salisbury, state of Maryland and Spokane, state of Washington. The Company also has subsidiaries in USA, China and Belgium. Together, these help Jubilant cater to 130 customers across more than 50 countries around the world.

The Company has 4000 employees across its locations. Jubilant is headquartered in NOIDA (state of Uttar Pradesh), India.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.


'/>"/>
SOURCE HollisterStier Laboratories LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation
2. Radio wave cooling offers new twist on laser cooling
3. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
4. Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies
5. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
8. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
9. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
10. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
11. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
Breaking Biology News(10 mins):